Epigenetics and therapeutic targets in gastrointestinal malignancies

Area of Science:

• Oncology
• Epigenetics
• Molecular Biology

Background:

• Gastrointestinal (GI) malignancies contribute significantly to global mortality and morbidity.
• Dysregulated signal transduction and epigenetic pathways, controlled by enzymes, promote GI cancers.
• Histone deacetylases (HDACs) and DNA methyltransferases (DNMTs) play critical roles in GI regulation.

Purpose of the Study:

• To review enzyme targets and their mechanisms in GI malignancy regulation.
• To discuss epigenetic therapeutic targets, particularly DNMT and HDAC inhibitors.
• To examine the clinical outcomes of these epigenetic therapies in GI malignancies.

Main Methods:

• Literature review of studies on enzyme targets in GI malignancies.
• Analysis of functional mechanisms of HDACs and DNMTs in GI cancer.
• Evaluation of clinical data on DNMT and HDAC inhibitors for GI malignancies.

Main Results:

• HDACs and DNMTs are key regulators in GI cancer development.
• Epigenetic inhibitors targeting DNMTs and HDACs show therapeutic potential.
• These inhibitors have demonstrated functional consequences and clinical outcomes in GI malignancies.

Conclusions:

• Enzyme targets like HDACs and DNMTs are crucial in GI malignancies.
• Epigenetic therapies offer promising avenues for GI cancer treatment.
• Further research into DNMT and HDAC inhibitors is warranted for improved clinical outcomes.